- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00306228
Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty (GRACIA3)
A Randomised Trial to Evaluate the Role of Paclitaxel Eluting Stent and Tirofiban to Improve the Results of Facilitated PCI in the Treatment of Acute ST- Segment Elevation Myocardial Infarction
The conceptual hypothesis of this study is that, in patients with acute myocardial infarction and ST-segment elevation, the strategy of performing coronary angioplasty of the culprit artery with paclitaxel eluting stent significantly reduces the rate of restenosis in comparison with bare stents.
The conceptual hypothesis of this study is that, in patients with acute myocardial infarction and ST-segment elevation, the strategy of performing coronary stent-angioplasty of the culprit artery under the protection of tirofiban 120 minutes after fibrinolytic significantly improves epicardial and myocardial infusion in comparison with the strategy of performing immediate intravenous thrombolysis (tenecteplase plus enoxaparine) followed by coronary angiography and adequate revascularization.
Study Overview
Status
Conditions
Detailed Description
The primary objectives of this study are: first to determine the efficacy of paclitaxel eluting stent compared to conventional bare stent in terms of restenosis, and second to determine the effect of tirofiban administered prior to percutaneous coronary intervention (PCI) but 120 minutes after thrombolytic on the epicardial and myocardial flow after mechanical revascularization in patients with STEMI.
Methods: This is a phased 4, 2x2 randomised, open, multicenter, clinical study. Patients will be randomised 1:1:1:1 to four groups: a) paclitaxel eluting stent with tirofiban, b) paclitaxel eluting stent without tirofiban, c) bare stent with tirofiban and d) bare stent without tirofiban. A total of approximately 436 patients, with <12 hours STEMI will be enrolled. All patients will be initially treated with tenecteplase (TNK) and enoxaparin. Tirofiban will start 120 minutes after tenecteplase administration in those patients randomised to tirofiban. Cardiac catheterization will be performed within the first 3-12 hours after the study inclusion and stenting on the culprit artery, with the randomised paclitaxel or bare stent, will be performed.
The efficacy of these strategies will be measured in terms of: 1) binary restenosis, defined as >50% diameter stenosis and segment analysis including the stented segment as well as their margins, 5 mm proximal and distal to the stent at 9-12 months follow-up and, 2) the assessment of the epicardial and myocardial perfusion (%TIMI 3, CTFC, CFR-CTFC, TMP y DSA-TMP and the analysis of the normalization of the ST segment at 90 minutes, 3, 6, 12 and 24 hours after thrombolysis).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Valladolid, Spain, 47005
- Instituto de Ciencias del Corazón (ICICOR). Hospital Clínico Universitario de Valladolid
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with ST-segment elevation acute myocardial infarction with all of the following criteria will be eligible for enrollment:
- Age >18 years.
- Chest discomfort >30 minutes with no response to nitroglycerin.
- Time from the onset of symptoms to randomization < 12 hours.
- ST segment elevation > 1 mm in two or more limb leads or 2 mm in two or more contiguous precordial leads or non-diagnostic ECG (left bundle branch block or pacemaker rhythm) with classic symptoms.
- Killip class > 3.
- Written informed consent will be obtained.
Exclusion Criteria:
Patients presenting with any of the following will not be included in the study.
- Cardiogenic shock defined as a systolic blood pressure <90 mm Hg without response to fluid administration or <100 mmHg in patients with supportive treatment and no bradycardia.
- Suspected mechanical complications of acute myocardial infarction.
- Previous CABG.
- Non-cardiac disease that is likely to jeopardize the planned termination of the study.
- Woman of childbearing potential unless a negative pregnant test.
- Active bleeding and recent (within 2 weeks) surgery that contraindicate the use of heparin, tirofiban, or platelet aggregation inhibitors.
Contraindications for thrombolytic use.
- previous hemorrhagic stroke at any time
- history of prior non-hemorrhagic cerebrovascular accident within 12 months
- intracerebral neoplasia
- active internal bleeding
- suspected aortic dissection
- Uncontrolled hypertension >180/110 in several measurements
- any other known intracerebral pathology not covered in contraindications
- Current use of anticoagulants or heparin use within 8 hours
- known bleeding diathesis
- recent trauma (< 4 weeks), including head trauma or traumatic or prolonged (>10 minutes) CPR or recent major surgery or biopsy (<8 weeks)
- noncompressible vascular punctures
- recent (< 4 weeks) internal bleeding
- pregnancy
- active peptic ulcer
- History of hypersensitivity to aspirin, ticlopidine, clopidogrel, heparin, tirofiban and stainless steel.
- Known renal failure, creatinine >2,5 mg/dL.
- Known impaired hepatic function that contraindicates the use of clopidogrel.
- Known thrombocytopenia (100.000).
- Participation in other trial.
- Known multivessel disease identified as no suitable for revascularization.
- Known peripheral vascular disease that difficult cardiac catheterization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: bare-metal stent without tirofiban
implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
|
implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
|
Active Comparator: bare-metal stent with tirofiban
implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
|
implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
|
Active Comparator: paclitaxel-eluting stent without tirofiban
implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
|
implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
|
Active Comparator: paclitaxel-eluting stent with tirofiban
implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
|
implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
to determine the efficacy of paclitaxel eluting stent compared to conventional bare stent in terms of restenosis
Time Frame: 12 months
|
12 months
|
to determine the effect of tirofiban administered prior to PCI but 120 minutes after thrombolytic on the epicardial and myocardial flow after mechanical revascularization in patients with STEMI
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
to determine the safety of paclitaxel eluting stent in terms of rate of complications, and particularly acute and subacute total occlusion.
Time Frame: 12 months
|
12 months
|
to determine the interaction of paclitaxel eluting stent and the complicated myocardial infarction lesion in terms of reduction of intimal proliferation as evaluated by quantitative coronary angiography
Time Frame: 12 months
|
12 months
|
to determine the efficacy of paclitaxel eluting stent in different subgroups of patients: diabetics, small vessel (<2.5 mm), long lesion (>15 mm), gender, and tirofiban use.
Time Frame: 12 months
|
12 months
|
to determine the efficacy and safety of full dose fibrinolytic therapy plus delayed tirofiban compared to fibrinolytic therapy alone in different subgroups: diabetics and the elderly
Time Frame: 30 days
|
30 days
|
to determine the efficacy of use of tirofiban in relation to time to fibrinolytic therapy and time to mechanical revascularization.
Time Frame: 24 hours
|
24 hours
|
to determine possible interactions between the paclitaxel eluting stent and tirofiban in terms of restenosis or acute and subacute total occlusion following coronary stenting.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Francisco Fernandez-Aviles, MD, PhD, ICICOR, Hospital Clínico Universitario Valladolid, Spain
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRACIA 3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
Clinical Trials on Postfibrinolysis percutaneous coronary intervention
-
Mid and South Essex NHS Foundation TrustImperial College LondonRecruitingStable Angina | Chronic Total Occlusion of Coronary ArteryUnited Kingdom
-
University Hospital, SaarlandCompletedAcute Myocardial InfarctionGermany
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Artery DiseaseChina
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
Yonsei UniversityUnknownCoronary Artery Disease | Stable Angina | Unstable AnginaKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
RobocathCompletedCoronary Artery Disease | Percutaneous Coronary InterventionFrance, Belgium, Luxembourg, Netherlands
-
University College, LondonNational Institute for Cardiovascular Outcomes Research; British Cardiovascular... and other collaboratorsCompletedPercutaneous Coronary InterventionUnited Kingdom
-
Niels Ramsing HolmJohnson & JohnsonUnknown